It is possible to consider that in resemblance to CVD, classical metrics of HDLs, including plasma HDLc and apolipoprotein A-I, do not reflect the functional properties of HDLs in breast cancer that may have the contribution of other components of HDLs including bioactive lipids, antioxidant enzymes, and microRNAs (miRs) [1]. The gene discussed is APOA1; the disease is breast carcinoma.